5 Best Small-Cap Stocks To Buy Now

4. Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Number of Hedge Fund Holders: 20

Prometheus Biosciences, Inc. (NASDAQ:RXDX) was incorporated in 2016 and is headquartered in San Diego, California. It is a biopharmaceutical company, focused on the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases. 

On November 1, Stifel analyst Annabel Samimy raised the price target on Prometheus Biosciences, Inc. (NASDAQ:RXDX) to $55 from $50 and kept a Buy rating on the shares ahead of Phase 2 data for ARTEMIS-UC and APOLLO-CD due in Q4 2022. The analyst is “generally optimistic” that PRA023 can achieve 10%-15% pbo-corrected clinical remission in ARTEMIS-UC, categorizing this as “the range of typical UC biologics and minimal bar for approvability.” 

According to Insider Monkey’s data, 20 hedge funds were bullish on Prometheus Biosciences, Inc. (NASDAQ:RXDX) at the end of June 2022, compared to 17 funds in the preceding quarter. Bihua Chen’s Cormorant Asset Management is the leading stakeholder of the company, with more than 2 million shares worth $57.2 million. 

Follow Prometheus Biosciences Inc.